BACKGROUND With the large number of women having mammography-an estimated 28.4 million U.S. women aged 40 years and older in 1998-the percentage of cancers detected as ductal carcinoma in situ (DCIS), which has an uncertain prognosis, has increased. We pooled data from seven regional mammography registries to determine the percentage of mammographically detected cancers that are DCIS and the ra...

Diagnosis of breast preneoplastic and neoplastic lesions is difficult due to their similar morphology in biopsy specimens. To diagnose these lesions, pathologists perform immunohistochemical analysis consult with expert pathologists. These additional examinations are time-consuming expensive. Artificial intelligence (AI)-based image has recently improved, may help ordinal pathological diagnosis...

Recent reports suggest that the finding of lobular neoplasia (atypical lobular hyperplasia [ALH] or lobular carcinoma in situ [LCIS]) in breast core needle biopsy specimens may be associated with an increased risk of both ductal carcinoma in situ (DCIS) or invasive carcinoma at excision. We reviewed our breast core biopsy material to see if we could confirm this finding. From 4,297 biopsies, 71...

AIMS Ductal carcinoma in situ (DCIS) of the breast has been diagnosed increasingly since the advent of mammographic screening. In contrast to the situation in invasive breast carcinoma, there are no reports on androgen receptor (AR) status in DCIS and few reports on oestrogen (ER) and progesterone (PR) receptors. METHODS AR expression was examined in 57 cases of DCIS of the breast and correla...

Mammary ductal carcinoma in-situ (DCIS), a malignant appearing lesion on cytological and histological grounds, is in fact a non-obligate precancer. DCIS is difficult to manage and is sometimes treated more aggressively than invasive carcinoma. Although most DCIS classifications take into account the architectural growth pattern, when it comes to architecture, the literature is full of contradic...

UNLABELLED BACKGROUND Lysine-specific demethylase1 (LSD1) is a nuclear protein which belongs to the aminooxidase-enzymes playing an important role in controlling gene expression. It has also been found highly expressed in several human malignancies including breast carcinoma. Our aim was to detect LSD1 expression also in pre-invasive neoplasias of the breast. In the current study we therefor...

Flow cytometric DNA analysis was performed on unfixed frozen tissue samples from 48 cases of invasive breast cancer (IC) with a predominance of ductal carcinoma in situ (DCIS). In 15 cases the samples contained only the DCIS component, in 17 cases only the IC component, whereas in 16 cases separate samples from the DCIS as well as the IC part within the individual lesion were available. In the ...

Until recently, there has been little knowledge on the growth control of oestrogen receptor (ER)-negative ductal carcinoma in situ (DCIS) and invasive breast cancer. The recent development of DCIS models, such as transgenic mice, cell-line xenograft models and, importantly, in vivo human DCIS xenograft models has facilitated the investigation and understanding of the control of growth of early ...

J-H. Chen, H. J. YU, H-M. Baik, M-Y. Su, O. Nalcioglu Tu &Yuen Center for Functional Onco-Imaging, University of California, Irvine, Irvine, CA 92697, United States, Department of Radiology, China Medical University Hospital, Taichung, Taiwan Purpose Ductal carcinoma in situ (DCIS) accounts for 80% of noninvasive breast carcinomas. Laboratory and patient data suggest that DCIS is a precursor le...

The relevance of 8 contemporary classification and grading systems for ductal carcinoma in situ (DCIS) of the breast was examined in 100 tumors by comparing DCIS grade with grade of the concurrent infiltrating ductal carcinoma (IDC). Besides tumor size and nodal status, the immunohistochemical parameters in both lesions were compared, including estrogen receptor, progesterone receptor, c-erbB-2...